Guerbet: Guerbet contributes to the NH TherAguix IPO on Euronext Growth, a specialist in innovative biotechnologies for precision radiotherapy
September 29 2021 - 12:00PM
Guerbet: Guerbet contributes to the NH TherAguix IPO on Euronext
Growth, a specialist in innovative biotechnologies for precision
radiotherapy
Guerbet contributes to the NH TherAguix
IPO on Euronext Growth, a specialist in innovative biotechnologies
for precision radiotherapy
Villepinte, September 29, 2021 (6:00
p.m. CET) – Guerbet (FR0000032526 GBT), a
global specialist in contrast agents and solutions for medical
imaging, has committed to contribute to the NH TherAguix IPO on
Euronext Growth market in Paris by placing an order of €3 million
as an institutional placement. This order represents approximately
9.99% of the gross proceeds of the offering, in the case of a fully
subscribed offering, excluding the exercise of the extension clause
and the over-allotment option.
NH TherAguix is a young French biotech company
founded in 2015 that specializes in the development of innovative
nanomedicines for the treatment of cancer by radiotherapy.
Guerbet’s investment comes as the two companies
have begun discussing a possible partnership for use of artificial
intelligence developed by Guerbet in NH TherAguix clinical trials
on the pancreas and glioblastoma. Last July, the two companies bid
together to obtain government funding in this field as part of an
Important Project of Common European Interest (IPCEI). Following on
from Guerbet’s subscription commitment, the two companies will
discuss possible areas for collaboration on the AGuIX platform,
with the objective to negotiate a partnership agreement.
François Nicolas, Vice President
R&D, R&I and Chief Digital Officer for Guerbet,
said: “This investment in NH TherAguix is in line with our
desire to pursue innovation in diagnostic imaging and to strengthen
our R&D pipeline by seeking partnerships with young innovative
companies whose research work may have strong complementarities
with our core business. We are therefore very excited to support
this IPO and thus confirm our interest in a theranostic
approach.”
About
Guerbet
At Guerbet, we build lasting relationships so
that we enable people to live better. This is our purpose. We are a
leader in medical imaging worldwide, offering a wide range of
pharmaceutical products, medical devices, digital and AI solutions
for diagnostic and interventional imaging. A pioneer since 95 years
in the field of contrast media with over 2,600 people globally, we
are continuously innovating with 10% of revenue dedicated to
Research & Development and four centers in France, Israel and
the United States. Guerbet (GBT) is listed on Euronext Paris
(segment B – mid caps) and generated €712 million in revenue in
2020.
For more information about Guerbet, please visit
www.guerbet.com.
Contacts
Anne-Laure DelasalleGlobal Communications Director
+33 (0)1 45 91 50 03anne-laure.delasalle@guerbet.com |
|
Jennifer JulliaMedia Relations+33 (0)1 56 88 11
19jjullia@actifin.fr |
Guerbet (LSE:0ELV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Guerbet (LSE:0ELV)
Historical Stock Chart
From Apr 2023 to Apr 2024